Evidence map›Paper›PMID 31216216›Full record

SynthesisHuman vaccines & immunotherapeutics2019

A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines.

Ashleigh McGirr, Shehzad M Iqbal, Patricia Izurieta, Carla Talarico, Janneke Luijken, Josefine Redig, Rachel S Newson

Open access · hybridAbstract readComparative StudySystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Comparative efficacy of ofatumumabTherapeutic advances in neurological disorders · 2024
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Ashleigh McGirrGSK, Mississauga, Ontario, Canada.ORCID 0000-0002-5570-8837
Shehzad M IqbalGSK, Mississauga, Ontario, Canada.
Patricia IzurietaGSK, Wavre, Belgium.
Carla TalaricoGSK, Rockville, MD, USA.
Janneke LuijkenICON plc, Houten, The Netherlands.ORCID 0000-0001-9580-2994
Josefine RedigICON plc, Stockholm, Sweden.ORCID 0000-0001-7904-7511
Rachel S NewsonICON plc, Houten, The Netherlands.
GlaxoSmithKline (Canada) · CAImperial Consultants · GBGlaxoSmithKline (Belgium) · BEGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Vaccine PotencyCase-Control StudiesChild, PreschoolCost-Benefit AnalysisFeasibility StudiesHaemophilus influenzaeHumansInfantPneumococcal InfectionsPneumococcal VaccinesRandomized Controlled Trials as TopicVaccines, Conjugate13-valent pneumococcal vaccinePneumococcal VaccinesVaccines, Conjugatecomparative efficacy or effectivenessfeasibilityinvasive pneumococcal diseasenetwork meta-analysisPneumococcal conjugate vaccinesystematic review

Identifiers

PMID31216216
PMCPMC6930063
OpenAlexW2953252172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.